GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Lumosa Therapeutics Co 6535.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

71.50

+1.85%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Lumosa Therapeutics Co

Its shares trade on Taipei Exchange under the ticker 6535.TWO. It has been listed since 16 July 2015. In the fiscal year to 31 December 2025, it reported revenue of TWD 35.8m and a net loss of TWD 340.5m. At that date it held total assets of TWD 1.65bn and shareholders' equity of TWD 1.51bn.

Lumosa Therapeutics Co., Ltd. engages in the development of drugs for the central nervous system, oncology, and inflammatory diseases. The company is headquartered in Taipei City, Taipei. The company went IPO on 2015-07-16. The firm is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The firm is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
16 Jul 2015
Employees
47

Leadership

Pay as last reported

  • Mr. Jung-Chin LinChairman of the Board, General Manager, since 2016
  • Ms. Su-Chi WangChairman of the Board, since 2024
  • Ms. Peijun ChenChief Operating Officer
  • Shengwen YeGeneral Manager
  • Ms. Lanying HuangHead of Finance & Accounting
  • Jialing LinDirector
  • Xueling WangDirector
  • Mr. Wanlai ZhengDirector
  • Zhiyong JinIndependent Director
  • Xinrong LinIndependent Director
  • Ms. Haiyi MaIndependent Director
  • Zhixiong WuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Lumosa Therapeutics focuses on CNS, oncology, and inflammatory disease drug development with 47 employees.
  • The company's reSEARCH and DEVELOPMENT model supports scientific licensing and new drug creation.
  • Lumosa Therapeutics has an IPO listing date of 16 July 2015 for pharmaceutical innovation.

Weaknesses

  • Lumosa Therapeutics operates with only 47 full-time employees in the Health Care sector.
  • The company's headquarters in Taipei City, Taiwan, may limit global market reach.
  • Lumosa Therapeutics has no mention of major partnerships or collaborations in the facts.

Opportunities

  • The Health Care sector in Taiwan offers growth potential for CNS and oncology drug development.
  • Expanding into inflammatory disease treatments could address unmet medical needs globally.
  • The reSEARCH and DEVELOPMENT model may attract scientific licensing opportunities.

Threats

  • Competition in the Pharmaceuticals industry requires significant R&D investment.
  • The Health Care sector faces regulatory challenges in Taiwan and global markets.
  • Lumosa Therapeutics' small employee count may hinder rapid market expansion.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.